48 results about "Sialyl LeA" patented technology

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

In a method for treating cancer by desialylation of sialylated glycans expressed on the surface of cancer cells, the present invention provides a method for extending the serum half-life of the active ingredient, sialidase, and enhancing the therapeutic effect of said sialidase. [Solution] A pharmaceutical composition is provided that contains sialidase which, when administered to a subject, conjugates to a serum half-life enhancing factor that increases the serum half-life of sialidase.

The present invention provides a drug delivery system for penetrating the blood-brain barrier, which is obtained by binding sialyllactose, which is capable of penetrating the blood-brain barrier, to a drug. The drug delivery system can deliver not only small molecular weight drugs, but also antibodies, which have a large molecular weight, to the brain, and is therefore applicable to various brain disease treatments and diagnostic substances.

A method of treating an aging-related disorder includes identifying a subject having an aging-related disorder and administering to the subject a therapeutically effective amount of a desialylated O-glycosylated glycoprotein, wherein the therapeutically effective amount is between 0.1 mg / kg and 500 mg / kg with respect to a body weight of the subject. Also disclosed are methods for producing the desialylated O-glycosylated glycoprotein using a clonal cell lacking sialyltransferase activity.

The present invention relates to a composition for promoting intestinal development and its use. The composition comprises lactose-N-neotetraose and 3'-sialyllactose. The composition for promoting intestinal development according to the present invention can upregulate the transcription levels of intestinal glycocalyx development-related genes HAS1, HAS2, and HAS3, as well as the transcription level of EXT2, thereby synergistically promoting intestinal glycocalyx development.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

To provide a method for treating a patient by using an IgG pharmaceutical highly added with sialic acid.SOLUTION: A method for treating a disease includes administering an hsIgG pharmaceutical to a subject by 1% to 10% dosage of an effective dosage of IVIG in order to treat the disease.SELECTED DRAWING: None

To provide nucleic acids encoding human antibodies to Sialyl-Lewis a.SOLUTION: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa(sLea). The compositions of the invention include polynucleotides encoding a heavy chain and / or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation. The antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that have an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.SELECTED DRAWING: Figure 1

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The present invention provides isolated monoclonal antibodies that specifically bind to Sialyl Lewis A (SLeA) glycan, fragments thereof and humanized version of said antibodies or fragments, as well as conjugates thereof. The invention further provides chimeric antigen receptors comprising said antibodies or fragments and cells, such as T cells comprising same. The invention further provides pharmaceutical compositions comprising all of the above agents and use of said agents and compositions for diagnosing and treating cancer characterized by overexpression of SLeA.

Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age≥35 are described.

This application relates to nucleic acids encoding human antibodies against sialyl Lewis a antigen. The present invention provides compositions for generating antibodies or functional fragments thereof against sialyl Lewis a antigen (sLe<supgt;a< / supgt;). The compositions of the present invention include polynucleotides encoding the heavy chain and / or light chain variable domains that bind to sLe<supgt;a< / supgt>. The present invention also provides isolated antibodies or functional fragments thereof and methods for treating or preventing diseases such as cancer or tumor formation, wherein the antibodies or functional fragments include heavy chain variable domains and light chain variable domains having the amino acid sequences provided herein. The present invention also provides conjugates of antibodies or functional fragments thereof conjugated or recombinantly fused with diagnostic reagents, detectable reagents or therapeutic agents, and methods for treating, preventing or diagnosing diseases in a subject in need thereof.

Methods of treating an autoimmune disorder affecting the skin and / or the kidneys, e.g., epidermal bullosa acquisita (EBA) or glomerulonephritis in a human subject thereof, using a population of highly sialylated immunoglobulin Fc polypeptides having an amino acid substitution from phenylalanine to an aliphatic amino acid residue, such as alanine, at amino acid residue 241 of the Fc heavy chain.

The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions targeting GM2-expressing tumor cells for the treatment and prevention of cancer.

The present invention concerns the field of antibodies. More specifically, it relates to an antibody that specifically binds to hypoglycosylated MUC1, wherein said antibody binds to an epitope formed by a carbohydrate moiety of the hypoglycosylated MUC1 and by a peptide backbone portion of the MUC1 protein. The present invention also relates to said antibody for use in in treating and / or preventing cancer associated with aberrant cancer specific MUC1 expression and, preferably, adenocarcinoma. Moreover, the present invention refers to VAST bound immunogen for use as a vaccine, wherein said VAST-bound immunogen comprises a peptide having an amino acid sequence as shown in SEQ ID NO: 92 (PAHGVTSAPDTRPAPGSTAP) wherein sialyated N-acetylgalactosamine (GalNAc) is linked to the serine residue at position 17 or threonine residue at position 18 in SEQ ID NO: 92 by a glycosidic bond. The invention also relates to method for manufacturing an antibody that specifically binds to hypoglycosylated MUC1, said method comprising the step of obtaining the antibody from a sample of an animal which has been immunized with a VAST-bound immunogen, wherein said immunogen comprises a peptide having an amino acid sequence as shown in SEQ ID NO: 92 (PAHGVTSAPDTRPAPGSTAP), wherein sialyated N-acetylgalactosamine (GalNAc) is linked to the serine residue at position 17 or threonine residue at position 18 in SEQ ID NO: 92 by a glycosidic bond.

A method for predicting curative effect of glioblastoma and preparing related drugs belongs to the field of biological medicine, and characterizes N-glycome spectrums in a cerebrospinal fluid sample paired before and after treatment of a glioblastoma patient by using a hydrophilic interaction liquid chromatography combined fluorescence detection and mass spectrometry technology. After chromatographic and mass spectrometric data are analyzed by a computer, the treatment effect of glioblastoma, especially the treatment effect of apatinib, can be predicted or judged through changes of LacdiNAc, sialylation level and core fucosylation level, guidance is provided for a patient to select a treatment scheme, and the method can be used for preparing a medicine for treating glioblastoma.

The invention discloses a chimeric transformation receptor based on a macrophage immune checkpoint Siglec9 and application of the chimeric transformation receptor. The chimeric transformation receptor comprises an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain is an extracellular structural domain of a human Siglec9 receptor or functional homologues of other species; the transmembrane domain is a transmembrane structural domain of CD8 or CD28; the intracellular domain is selected from the group consisting of intracellular signaling domains of CD3 [zeta], FcR [gamma], TLR4, CD40, Megf10, Dectin-1, or a combination thereof. The chimeric transformation receptor based on the macrophage immune checkpoint Siglec9 is expressed on the surface of the macrophage, so that after sialic acid glycan on the surface of a tumor cell is combined with the chimeric transformation receptor on the surface of the macrophage, the macrophage is driven to be transformed into an anti-tumor M1 phenotype; the engineering macrophages are promoted to always keep an effective killing capability state on tumor cells, and the killing effect of an immune cell therapy on the tumor cells is exerted and amplified, so that an efficient and lasting anti-tumor effect is obtained.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The present invention provides novel ligand compounds that specifically bind to inhibitory Siglecs (e.g., Siglec 7 and Siglec 9). The novel Sig7 / 9 ligands and related drug conjugates described herein are capable of inhibiting recruitment of Sig7 / 9 by tumor cells to phagocytic and immunological synapses. By promoting Sig7 / 9 sequestration and degradation, the compositions and methods of the invention enhance cancer immune therapy via suppressing Sig7 / 9-mediated inhibition of both innate adaptive immune cell activation and functions.

The present invention relates to a method for producing α-2,6-sialylated immunoglobulin using plasma cells isolated from humans. The present invention makes it possible to mass produce α-2,6-sialylated immunoglobulin (2,6 IG) without using human blood, and it was discovered that α-2,6-sialylated immunoglobulin (2,6 IG) produced by the present invention can increase the level of IL-10, which is representative of an immunosuppressive cytokine produced by DC-SIGN stimulation. Thus, the method according to the present invention can be effectively used as an immunoglobulin substitute capable of replacing IVIG.

Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.

To provide an alternative antibody therapy targeting glycan epitopes.SOLUTION: Provided is an antibody or antigen-binding portion thereof that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the binding affinity of the antibody or antigen-binding portion to sLeA is a KD of 60 μ M or less and the binding affinity to sLeC is a KD of 100 μ M or less. Also provided are polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.SELECTED DRAWING: Figure 2C

The subject matter of the present disclosure provides methods and compositions for treating cancer (e.g., pancreatic cancer). It relates to antigen recognition receptors (e.g., chimeric antigen receptors (CARs)) that specifically target sialyl Lewis A (e.g., human sialyl Lewis A), and immune response cells comprising such CARs. The sialyl Lewis A-specific CARs of the present disclosure have enhanced immune activation properties, including anti-tumor activity.

Disclosed are an antibody or a functional fragment thereof binding to 3′-sialyl lactose and comprising a heavy chain variable region which is optionally substituted with 3 or less amino acids and which comprises a CDR sequence consisting of an amino acid sequence ARKNGGLDYAMDY (SEQ ID NO: 3), a polynucleotide encoding the antibody or the functional fragment thereof, an expression vector comprising the polynucleotide, and a test drug for a disease and a pharmaceutical composition comprising the antibody or the functional fragment thereof.

The invention provides application of an N-glycan marker, a fetal and neonatal hemolytic disease prediction model and a fetal and neonatal hemolytic disease prediction device. The following characteristics (a) or (b) of pregnant woman plasma N-glycan serve as the marker for predicting fetal and neonatal hemolytic diseases: (a) abundance of one or more sugar chain types: H5N4S2, H4N5F, H5N5S2, H6N5S2, H6N5S3 and H6N5FS3; (b) abundance of one or more of the following glycosylation characteristics: high branch structure, low branch structure, tri-sialylation, tri-galactosylation, double-galactosylation, outer arm fucosylation. The marker has a significant difference in HDFN and non-HDFN pregnant woman plasma, and can be used as a marker for predicting the fetal and neonatal hemolytic diseases, and a prediction model constructed based on the marker can accurately predict whether a subject suffers from the fetal and neonatal hemolytic diseases or judge the risk of the subject suffering from the fetal and neonatal hemolytic diseases.

Glycopeptides derived from short CD44 isoforms lacking amino acids encoded by exons 6-14; presenting one or multiple serine or threonine residues substituted with Tn (GalNAcα-O-Ser / Thr) and / or sialyl-Tn (STn; Neu5Acα2-6GalNAcα-O-Ser / Thr) antigens. Synthesizing the glycopeptides, including one-pot glycosylation of synthetic short isoform CD44 peptides through combination with nucleotide sugars and glycosyltransferases and purification of CD44s-Tn glycopeptides. Immunogenic chimeras derived from the CD44-Tn and / or STn glycopeptides, linked, in polyvalent form, to a carrier immunogenic protein, e.g., KLH CRM197. Conjugating the synthesized CD44s-Tn glycopeptides to the immunogenic protein carriers CRM197 and KLH, generating chimeric glycopeptides, termed CRM197-CD44s-Tn and KLH-CD44s-Tn. CD44-Tn / STn glycopeptides or compositions thereof for treating cancer and pre-neoplastic diseases, e.g., neoplastic diseases expressing short CD44 isoforms, through generating antibodies against cancer cells and treating / preventing cancer by vaccination. The glycopeptides, compositions, synthesis methods and uses can be employed in treating cancer, alone or in combination with immune checkpoint inhibitor therapy, chemotherapy, and radiotherapy.

The present invention relates to biomarkers, methods and assay kits for predicting prognosis and / or monitoring progression of prostate cancer. The biomarkers include a glycosyltransferases [core 1 beta-3-galactosyltransferase (C1GALT1) and / or ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1)] gene product, its saccharide substrate / product, and / or a galectin-4 gene product.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.

This disclosure is based, at least in part, on an unexpected discovery that coexpression of both type I Fc receptor (e.g., FcyRIIB) and type II Fc receptor (e.g., DC-SIGN) augments the binding of IVIG and its active component, sialylated Fc. The disclosed Fc variants can achieve a significant enhancement of in vivo protection as compared to IVIG in several models of autoantibody mediated inflammation.